ArticleClinical, cosmetic and investigational dermatology2026
A Real-World Study of Polynucleotides HPT for Treating Periorbital Hyperpigmentation.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Multimodal Approach to Extended Periorbital Rejuvenation: Clinical Outcomes and Time Course in a Prospective Single-Centre Study.Clinical, cosmetic and investigational dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and Purpose: Anatomic factors and age‑related changes in the midface, along with sun exposure, prolonged television viewing, anemia, and hormonal derangements, contribute to the development of periorbital hyperpigmentation, also known as dark circles. Intradermally injected PN HPT (Polynucleotides High Purification Technology) from trout gonads has an immediate volume-enhancing effect and a longer-term indirect restructuring action on dermal and subdermal tissues. Methods: Open-label multinational observational cohort of 61 real-life multinational subjects of both genders and unskewed age distribution (mean 41.5 ± 10.5 years, range 20 to 67), with subjectively disturbing dark circles across all Huang subtypes. PN HPT hydrogel (7.5 mg/mL) in phosphate buffer was administered with needle or cannula at baseline (T0), after two to three weeks (second injection, T1), and two to three weeks after T1 (third injection, T2); usually 1 mL on the right periorbicular area and 1 mL on the left (lower doses allowed at the specialist's discretion). Post-treatment follow-up visits: Snapshot photographs were taken at 1 month (T3) and three months after the final T2 injection (T4) and digitally analyzed for color, pigmentation, and outcomes compared with T0 (primary endpoint). Every participating specialist and every treated subject also assessed hyperpigmentation and skin quality categories with GAIS-like scoring scales. Results: Regarding the primary endpoint, the overall picture showed a generalized, highly significant shift toward less severe periorbital hyperpigmentation (p <0.001), especially among needle-treated subjects with the structural subtype. The progressive improvements at T3 and T4 in the evaluated perceptual skin quality categories were also remarkable for both participating specialists and treated subjects. Conclusion: The double-edged rationale of low-concentration PN HPT - immediate correction of hollows and tissue loss, and longer-term restructuring of periorbital connective tissues - may be a sound option for improving the appearance of dark circles and the lives of subjects with this aesthetic nuisance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.